Literature DB >> 7634380

Taxol cytotoxicity on human leukemia cell lines is a function of their susceptibility to programmed cell death.

R M Gangemi1, M Tiso, C Marchetti, A B Severi, M Fabbi.   

Abstract

Taxol is the prototype of a class of antineoplastic drugs that target microtubules. It enhances tubulin-monomer polymerization and stabilizes tubulin polymers, increasing the fraction of cells in the G2 or M phase of the cell cycle. We report that treatment of HL-60 and U937 myeloid cell lines with 1-10 microM taxol induces DNA fragmentation and the appearance of morphological features consistent with the process of apoptosis. Taxol-induced apoptosis is inhibited neither by cycloheximide nor by actinomycin D and therefore appears to be independent of new protein synthesis. Taxol causes arrest in the G2 phase of the cell cycle and affects cell viability but does not induce DNA fragmentation in the K562 erythromyeloid cell line. Protein-synthesis inhibitors, colcemid, ionomycin, and starvation, known to trigger apoptosis, proved ineffective as well. These results suggest that the antineoplastic effect of taxol is mediated in susceptible cell lines by induction of the apoptotic machinery and that K562 partial resistance may depend upon the intrinsic inability of these tumor cells to undergo apoptosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7634380     DOI: 10.1007/BF00686187

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  28 in total

1.  Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia.

Authors:  M A Barry; C A Behnke; A Eastman
Journal:  Biochem Pharmacol       Date:  1990-11-15       Impact factor: 5.858

2.  Disruption of microtubules induces an endogenous suicide pathway in human leukaemia HL-60 cells.

Authors:  S J Martin; T G Cotter
Journal:  Cell Tissue Kinet       Date:  1990-11

3.  Thymocyte apoptosis induced by p53-dependent and independent pathways.

Authors:  A R Clarke; C A Purdie; D J Harrison; R G Morris; C C Bird; M L Hooper; A H Wyllie
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

4.  Taxol, radiation, and oncogenic transformation.

Authors:  T K Hei; E J Hall
Journal:  Cancer Res       Date:  1993-03-15       Impact factor: 12.701

5.  Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells.

Authors:  K Bhalla; A M Ibrado; E Tourkina; C Tang; M E Mahoney; Y Huang
Journal:  Leukemia       Date:  1993-04       Impact factor: 11.528

6.  Induction of apoptosis in human leukemic cells by the ether lipid 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine. A possible basis for its selective action.

Authors:  L Diomede; F Colotta; B Piovani; F Re; E J Modest; M Salmona
Journal:  Int J Cancer       Date:  1993-01-02       Impact factor: 7.396

Review 7.  Taxol: a novel investigational antimicrotubule agent.

Authors:  E K Rowinsky; L A Cazenave; R C Donehower
Journal:  J Natl Cancer Inst       Date:  1990-08-01       Impact factor: 13.506

8.  A phase II trial of taxol in metastatic melanoma.

Authors:  S S Legha; S Ring; N Papadopoulos; M Raber; R S Benjamin
Journal:  Cancer       Date:  1990-06-01       Impact factor: 6.860

9.  BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death.

Authors:  A McGahon; R Bissonnette; M Schmitt; K M Cotter; D R Green; T G Cotter
Journal:  Blood       Date:  1994-03-01       Impact factor: 22.113

10.  Development of polyploidization in taxol-resistant human leukemia cells in vitro.

Authors:  J R Roberts; D C Allison; R C Donehower; E K Rowinsky
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

View more
  11 in total

1.  Properties of cells through life and death - an acoustic microscopy investigation.

Authors:  Maurice M Pasternak; Eric M Strohm; Elizabeth Sl Berndl; Michael C Kolios
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 2.  Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.

Authors:  Hua Zheng; Masha Zeltsman; Marjorie G Zauderer; Takashi Eguchi; Raj G Vaghjiani; Prasad S Adusumilli
Journal:  Immunotherapy       Date:  2017-09       Impact factor: 4.196

3.  Differential effects of Paclitaxel on dendritic cell function.

Authors:  Justin John; Mohammed Ismail; Catherine Riley; Jonathan Askham; Richard Morgan; Alan Melcher; Hardev Pandha
Journal:  BMC Immunol       Date:  2010-03-19       Impact factor: 3.615

4.  Increased Protein Tyrosine Phosphorylation in Apoptotic Neural Cell Death Due to Microtubule Perturbations.

Authors:  Brett A Chromy; Mary P Lambert; William L Klein
Journal:  Neurotox Res       Date:  2000-12       Impact factor: 3.911

5.  Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia.

Authors:  Dawn E Colburn; Deborah A Thomas; Francis J Giles
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

6.  Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy.

Authors:  Abhalaxmi Singh; Fahima Dilnawaz; Sanjeeb Kumar Sahoo
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

7.  Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro.

Authors:  A J Terzis; F Thorsen; O Heese; T Visted; R Bjerkvig; O Dahl; H Arnold; G Gundersen
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Evidence of p53-induced apoptosis in cancer cells exposed to taxol.

Authors:  C A Bachman; D A Bills; S K Majumdar
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998-06       Impact factor: 2.723

9.  Suppression of anti-microtubule agent-induced apoptosis by nitric oxide: possible mechanism of a new drug resistance.

Authors:  T Ogura; G DeGeorge; M Tatemichi; H Esumi
Journal:  Jpn J Cancer Res       Date:  1998-02

10.  Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status.

Authors:  B Smith-Sørensen; J Kaern; R Holm; A Dørum; C Tropé; A L Børresen-Dale
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.